药物焦点:布德索尼德及其在儿童胃肠道疾病中的作用
Sohail Aziz1, Maria Giovanna Puoti2, Amit Assa3
1Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Napels, Italy.
Journal of pediatric gastroenterology and nutrition
|October 27, 2025
概括
布德索尼德有效地治疗轻度至中度克罗恩病和性食道炎,为胃肠道疾病提供局部抗炎药物选择. 由于潜在的长期副作用,建议仔细监测.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 布德索尼德是一种局部葡萄糖皮质类药物,具有向的胃肠道输送和最小的全身效应.
- 它可用于各种胃肠道 (GI) 疾病的口服和直肠配方.
研究的目的:
- 审查婴儿和成人胃肠道疾病中布松胺的药理学概况,临床应用和指导方针建议.
- 为了评估布索尼德在克罗恩病,性结肠炎和性食道炎中的疗效和安全性.
主要方法:
- 随机对照试验和真实世界研究的叙述性综述.
- 对ESPGHAN/ECCO的指导方针建议进行分析.
主要成果:
- 布德索尼德在轻度至中度的乳房内科克罗恩病中有效诱导缓解,被推作为儿科患者的替代疗法.
- 布德索尼德配方显示出对远端/左侧性结肠炎的潜力,以及对性食道炎缓解的有希望的结果.
- 与全身性皮质类固醇相比,全身性副作用较少,但长期使用的风险包括生长抑制和HPA轴抑制.
结论:
- 当与疾病特征和患者因素保持一致时,布德索尼德是针对特定的肠道疾病的有价值的治疗方法.
- 它提供了一种有针对性的方法,与全身治疗相比,具有有利的安全概况,尽管监测至关重要.
- 进一步的研究可能会支持更广泛的应用,特别是在儿科患者和eosinophilic食道炎中.
关键词:
这是一种上腺抑制.孩子们的孩子们的孩子们的孩子们.皮质类固醇是什么埃索诺菲尔性食道炎 (eosinophilic esophagitis) 是一种导致食道炎的疾病.炎症性肠病是一种炎症性肠病.更多相关视频
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
1.5K
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
397
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...